Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.

Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM, Jayashankar L, Miotto P, Zignol M, Schito M.

Clin Infect Dis. 2019 Mar 18. pii: ciz219. doi: 10.1093/cid/ciz219. [Epub ahead of print]

PMID:
30883637
2.

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J.

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

3.

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.

CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz AL, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo YY, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B.

N Engl J Med. 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26.

4.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

5.

The Use of a Shared Services Model for Mycobacteriology Testing: Lessons Learned.

Stafford C, Atkinson-Dunn R, Buss SN, Dalton T, Gibson D, Johnston S, King E, Grace Lin SY, Mitchell KK, Murtaugh WA, Sease H, Southern TR, Tans-Kersten JL, Travanty EA, Triplett LR, Wroblewski K, Starks AM.

Public Health Rep. 2018 Jan/Feb;133(1):93-99. doi: 10.1177/0033354917743498. Epub 2017 Dec 19.

6.

Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States.

Yakrus MA, Driscoll J, McAlister A, Sikes D, Hartline D, Metchock B, Starks AM.

Tuberc Res Treat. 2016;2016:3404860. doi: 10.1155/2016/3404860. Epub 2016 Jun 8.

7.

Representativeness of Tuberculosis Genotyping Surveillance in the United States, 2009-2010.

Shak EB, France AM, Cowan L, Starks AM, Grant J.

Public Health Rep. 2015 Nov-Dec;130(6):596-601.

8.

Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.

Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, Gallarda J, Hanna D, Kim PS, Liwski R, Miotto P, Schito M, Zignol M.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S141-6. doi: 10.1093/cid/civ610.

9.

Evaluation of a u.s. Public health laboratory service for the molecular detection of drug resistant tuberculosis.

Yakrus MA, Metchock B, Starks AM.

Tuberc Res Treat. 2015;2015:701786. doi: 10.1155/2015/701786. Epub 2015 Feb 22.

10.

Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis.

Salamon H, Yamaguchi KD, Cirillo DM, Miotto P, Schito M, Posey J, Starks AM, Niemann S, Alland D, Hanna D, Aviles E, Perkins MD, Dolinger DL.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S50-7. doi: 10.1093/infdis/jiu816. Review.

11.

Evaluation of the Cepheid Xpert MTB/RIF assay.

Shinnick TM, Starks AM, Alexander HL, Castro KG.

Expert Rev Mol Diagn. 2015 Jan;15(1):9-22. doi: 10.1586/14737159.2015.976556. Epub 2014 Nov 6. Review.

12.

Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States.

Yakrus MA, Driscoll J, Lentz AJ, Sikes D, Hartline D, Metchock B, Starks AM.

J Clin Microbiol. 2014 Jun;52(6):1932-7. doi: 10.1128/JCM.00417-14. Epub 2014 Mar 19.

13.

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.

Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S.

J Clin Invest. 2014 Jan;124(1):398-412. doi: 10.1172/JCI71180. Epub 2013 Dec 9.

14.

Household income is associated with the p53 mutation frequency in human breast tumors.

Starks AM, Martin DN, Dorsey TH, Boersma BJ, Wallace TA, Ambs S.

PLoS One. 2013;8(3):e57361. doi: 10.1371/journal.pone.0057361. Epub 2013 Mar 1.

15.

Biological determinants of health disparities in prostate cancer.

Martin DN, Starks AM, Ambs S.

Curr Opin Oncol. 2013 May;25(3):235-41. doi: 10.1097/CCO.0b013e32835eb5d1. Review.

16.

MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.

Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.

Oncogene. 2013 Aug 29;32(35):4139-47. doi: 10.1038/onc.2012.424. Epub 2012 Sep 17.

17.

Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems.

Tyrrell FC, Budnick GE, Elliott T, Gillim-Ross L, Hildred MV, Mahlmeister P, Parrish N, Pentella M, Vanneste J, Wang YF, Starks AM.

J Clin Microbiol. 2012 Oct;50(10):3275-82. doi: 10.1128/JCM.01225-12. Epub 2012 Jul 25.

18.

Unexpected decline in tuberculosis cases coincident with economic recession - United States, 2009.

Winston CA, Navin TR, Becerra JE, Chen MP, Armstrong LR, Jeffries C, Yelk Woodruff RS, Wing J, Starks AM, Hales CM, Kammerer JS, Mac Kenzie WR, Mitruka K, Miner MC, Price S, Scavotto J, Cronin AM, Griffin P, LoBue PA, Castro KG.

BMC Public Health. 2011 Nov 7;11:846. doi: 10.1186/1471-2458-11-846.

19.

Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.

Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE.

Antimicrob Agents Chemother. 2011 May;55(5):2032-41. doi: 10.1128/AAC.01550-10. Epub 2011 Feb 7.

20.

Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis.

Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE.

Antimicrob Agents Chemother. 2009 Mar;53(3):1061-6. doi: 10.1128/AAC.01357-08. Epub 2008 Dec 22.

21.

The Fanconi anemia/BRCA gene network in zebrafish: embryonic expression and comparative genomics.

Titus TA, Yan YL, Wilson C, Starks AM, Frohnmayer JD, Bremiller RA, Cañestro C, Rodriguez-Mari A, He X, Postlethwait JH.

Mutat Res. 2009 Jul 31;668(1-2):117-32. doi: 10.1016/j.mrfmmm.2008.11.017. Epub 2008 Dec 3. Review.

23.

The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.

Paulsen MT, Starks AM, Derheimer FA, Hanasoge S, Li L, Dixon JE, Ljungman M.

Mol Cancer. 2006 Jun 19;5:25.

24.

The Fanconi anemia gene network is conserved from zebrafish to human.

Titus TA, Selvig DR, Qin B, Wilson C, Starks AM, Roe BA, Postlethwait JH.

Gene. 2006 Apr 26;371(2):211-23. Epub 2006 Mar 3.

PMID:
16515849
25.

Assembly of CS1 pili: the role of specific residues of the major pilin, CooA.

Starks AM, Froehlich BJ, Jones TN, Scott JR.

J Bacteriol. 2006 Jan;188(1):231-9.

26.

Molecular Pathogenesis of Vibrio vulnificus.

Gulig PA, Bourdage KL, Starks AM.

J Microbiol. 2005 Feb;43 Spec No:118-31. Review.

PMID:
15765065
27.

Pathogenesis of infection by clinical and environmental strains of Vibrio vulnificus in iron-dextran-treated mice.

Starks AM, Schoeb TR, Tamplin ML, Parveen S, Doyle TJ, Bomeisl PE, Escudero GM, Gulig PA.

Infect Immun. 2000 Oct;68(10):5785-93.

28.

Construction and phenotypic evaluation of a Vibrio vulnificus vvpE mutant for elastolytic protease.

Jeong KC, Jeong HS, Rhee JH, Lee SE, Chung SS, Starks AM, Escudero GM, Gulig PA, Choi SH.

Infect Immun. 2000 Sep;68(9):5096-106.

29.

Assessing continuing medical education needs in New Mexico.

Kantrowitz MP, DiVasto PV, Starks AM, Counsellor A, Orgel L.

West J Med. 1983 Jan;138(1):114-7.

Supplemental Content

Loading ...
Support Center